AgeX Therapeutics, Inc. (AGE)

NYSEAMERICAN: AGE · Delayed Price · USD
0.820
-0.117 (-12.49%)
At close: Jan 14, 2022 4:00 PM
0.795
-0.025 (-3.098%)
After-hours:Jan 18, 2022 8:00 PM EST
Market Cap31.11M
Revenue (ttm)622,000
Net Income (ttm)-8.96M
Shares Out37.94M
EPS (ttm)-0.24
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume211,037
Open0.810
Previous Close0.937
Day's Range0.750 - 0.835
52-Week Range0.516 - 3.060
Beta1.36
Analystsn/a
Price Targetn/a
Earnings DateNov 15, 2021

About AGE

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart. Its lead...

IndustryBiotechnology
IPO DateNov 29, 2018
CEOMichael West
Employees6
Stock ExchangeNYSEAMERICAN
Ticker SymbolAGE
Full Company Profile

Financial Performance

Financial Statements

News

AgeX Therapeutics to Collaborate With University of California, Irvine, on Research Program for Exosome-Based Therapi...

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced today a res...

1 month ago - Business Wire

AgeX Therapeutics' Licensee ImStem Biotechnology Announces First U.S. Multiple Sclerosis Patient Dosed with IMS001

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced today that ...

1 month ago - Business Wire

AgeX Therapeutics Receives Stock Exchange Deficiency Letter

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics , Inc. (“AgeX”: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on Novembe...

1 month ago - Business Wire

AgeX Therapeutics Reports Third Quarter 2021 Financial Results

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and opera...

2 months ago - Business Wire

AgeX Therapeutics Reports Second Quarter 2021 Financial Results

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and opera...

5 months ago - Business Wire

AgeX Therapeutics and LyGenesis Terminate Merger Negotiations

ALAMEDA, Calif. & PITTSBURGH--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and cell regeneration, and LyGenesis,...

5 months ago - Business Wire

AgeX Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and opera...

8 months ago - Business Wire

AgeX Therapeutics Reports Fourth Quarter and Annual 2020 Financial Results and Provides Business Update

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and opera...

9 months ago - Business Wire

AgeX Announces Preprint Article Relating to Regeneration, Aging, and Cancer

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today the online publi...

10 months ago - Business Wire

AgeX Therapeutics to Collaborate with The Ohio State University to Generate Proof-of-Concept Animal Data for AgeX's B...

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today a research colla...

10 months ago - Business Wire

AgeX Therapeutics and LyGenesis to Negotiate Merger Agreement

ALAMEDA, Calif. & PITTSBURGH--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and cell regeneration, and LyGenesis,...

10 months ago - Business Wire

AgeX Therapeutics, Inc. Announces That Its Annual Meeting of Stockholders Will Be Conducted Online Only

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE) announced today that due to state and county government health orders, attendance at the AgeX 2020 Annual Meeting o...

1 year ago - Business Wire

AgeX Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing innovative regenerative therapeutics to treat human diseases to increase health...

1 year ago - Business Wire

AgeX Therapeutics Sublicenses Stem Cell Line ESI-053 to ImStem Biotechnology for Development of Cell Therapy Candidat...

ALAMEDA, Calif. & FARMINGTON, Conn.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”: NYSE American: AGE), a biotechnology company developing innovative regenerative therapeutics to treat human disease...

1 year ago - Business Wire

AgeX Therapeutics News: Why AGE Stock Is Skyrocketing 193% Today

AgeX Therapeutics (AGE) stock is soaring higher on Thursday following news of that Juvenescence has a 50% stake in the company. The post AgeX Therapeutics News: Why AGE Stock Is Skyrocketing 193% Today ...

1 year ago - InvestorPlace